Hye Sung Kim

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)”.

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359241293401

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim +10 more

A Comprehensive Landscape of De Novo Malignancy After Double Lung Transplantation

Transplant International(2023)10.3389/ti.2023.11552

N/A

0DataRank · unranked

3 citations

Andrew Won Jun Yang, Liam Il‐Young Chung, Jisang Yu, Yunjoo Lee, Hye Sung Kim +5 more